Daily wakame seaweed to lower AGEs in adults with stage III CKD
Official title: Evaluation of the Effect of a Daily Dose of Wakame (Undaria Pinnatifida) on Reducing Circulating Concentrations of Advanced Glycation End Products (AGEs: Methylglyoxal) in Patients With Stage III Chronic Kidney Disease
Run by Groupe Hospitalier de la Rochelle Ré Aunis · NCT07729683 · Data updated 2026-11-12
This trial tests whether taking a daily wakame seaweed supplement can lower harmful AGEs in adults with stage III chronic kidney disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Groupe Hospitalier de la Rochelle Ré Aunis Academic / other |
| Locations | 1 site (La Rochelle) |
| Status | Recruiting |
| Started | January 27, 2026 |
| Main results expected | October 2027 |
| Study ends | October 2027 |
| Registry record updated | July 27, 2026 |
| Trial ID | NCT07729683 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-89 with stage IIIA-B CKD (eGFR 30–59 mL/min/1.73 m2) on optimized nephroprotective therapy.
✕Probably not a fit
Patients with unstable comorbidities, recent acute kidney injury, or those consuming other seaweed/iodine supplements may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study investigates whether daily consumption of wakame seaweed reduces circulating Advanced Glycation End Products (AGEs) in adults with stage III CKD. Participants will continue optimized nephroprotective therapy while taking the wakame supplement. The study focuses on the relationship between dietary AGEs and kidney function markers in a CKD population. Outcomes will inform whether wakame can modulate renal hemodynamics and AGE-related pathways in this group. Enrollment targets adults aged 18 to 89 with CKD stage IIIA-B and stable medical management.
Why it matters
Potential benefit: If successful, patients may experience lower AGE levels, which could be associated with slower CKD progression.
How similar studies have gone: Previous work suggests dietary factors can influence kidney function markers, but this specific wakame-AGE approach is novel in CKD.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients not under legal protection * Patients aged ≥ 18 and \< 90 years * Patients with stage IIIA-B chronic kidney disease (CKD) (estimated GFR by CKD-EPI ≥ 30 mL/min and \< 60 mL/min) * Patients receiving optimized nephroprotective treatment (ACE inhibitors, SGLT2 inhibitors) * Patients who have signed the informed consent form * Patients not participating in another clinical study * Patients affiliated with or benefiting from a social security scheme Exclusion Criteria: * Adult patients under legal protection * Patients under 18 years old or over 90 years old * Patients with uncontrolled thyroid disorders * Patients with decompensated heart failure * Patients consuming other dietary supplements containing seaweed or iodine (e.g., multivitamins) * Pregnant or breastfeeding women * Patients with acute kidney injury * Patients who decline to participate in the study
Where it's running
-
Groupe Hospitalier de La Rochelle Ré Aunis
La Rochelle, France Recruiting
Study contacts
- Study coordinator: Cécile Duchiron
- Email: cecile.duchiron@ght-atlantique17.fr
- Phone: +335 46 68 45 67
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational look at how Kremezin works in adults with advanced chronic kidney disease
This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.
-
Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China
This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
-
Arterial stiffness in children and young people with CKD and hypertension
This study will test whether arterial stiffness is higher in children and young people with chronic kidney disease and high blood pressure compared with their peers, using a one-time assessment and follow-up for those with high BP.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.